SCHEMBL6473582

SCHEMBL6473582

N#CN1c2ccccc2CC(=O)c2ccccc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.53
ALDH1A1 P00352 4/20 0.53
MEN1 O00255 4/20 0.53
KDM4E B2RXH2 3/20 0.53
MAPT P10636 2/20 0.53
CYP3A4 P08684 1/20 0.53
PABPC1 P11940 1/20 0.53
BLM P54132 1/20 0.53
CES1 P23141 2/20 0.43
BCHE P06276 1/20 0.43
HPGD P15428 4/20 0.41
HDAC1 Q13547 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
MAOA P21397 2/20 0.37
NOTUM Q6P988 2/20 0.37
CASP3 P42574 3/20 0.36
CASP6 P55212 3/20 0.36
SENP8 Q96LD8 2/20 0.36
SENP7 Q9BQF6 2/20 0.36
SENP6 Q9GZR1 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11506068 0.82 HPGD (0.38) KMT2AALDH1A1MEN1KDM4EMAPT
SCHEMBL949237 0.79 HPGD (0.50) KMT2AHPGDNOTUMCASP3CASP6
SCHEMBL10482902 0.78 ALDH1A1 (0.46) KMT2AALDH1A1MEN1KDM4EMAPT
SCHEMBL10482901 0.78 ALDH1A1 (0.46) KMT2AALDH1A1MEN1KDM4EMAPT
SCHEMBL6649905 0.74 ALDH1A1 (0.45) KMT2AALDH1A1MEN1MAPTCYP3A4
SCHEMBL7829086 0.74 ALDH1A1 (0.57) KMT2AALDH1A1MEN1KDM4EMAPT
SCHEMBL21311764 0.74 KMT2A (0.57) KMT2AALDH1A1MEN1KDM4EMAPT
SCHEMBL16835531 0.71 HPGD (0.64) KMT2AALDH1A1MEN1KDM4EMAPT
SCHEMBL13727309 0.70 POLB (0.47) ALDH1A1MAPTHPGDNOTUMCYP2A6
SCHEMBL24119281 0.70 KMT2A (0.53) KMT2AALDH1A1MEN1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4559174-A NITRATION, REDUCTION AND HYDROLYSIS OF 5-CYANO5H-DIBENZ/B,FLAZEPINE CIBA GEIGY CORPORATION (US) 1985-12-17 US claimed
EP-0028028-B1 PROCESSES FOR THE PREPARATION OF AN OXO COMPOUND, AND INTERMEDIATES REQUIRED THEREFOR CIBA-GEIGY AG (CH) 1985-05-22 EP claimed
EP-0028028-A2 Processes for the preparation of an oxo compound, and intermediates required therefor CIBA-GEIGY AG (CH) 1981-05-06 EP claimed
JP-1045367-A None JP disclosed
CN-120698931-A Preparation method of oxcarbazepine 河北科技大学 2025-09-26 CN disclosed
EP-2697662-B1 BIOCATALYTIC PROCESS FOR PREPARING ESLICARBAZEPINE AND ANALOGS THEREOF CODEXIS INC (US) 2018-06-06 EP disclosed
US-9963683-B2 Biocatalytic process for preparing eslicarbazepine and analogs thereof CODEXIS, INC. (US) 2018-05-08 US disclosed
US-9963683-B2 Biocatalytic process for preparing eslicarbazepine and analogs thereof CODEXIS, INC. (US) 2018-05-08 US disclosed
US-20170159028-A1 BIOCATALYTIC PROCESS FOR PREPARING ESLICARBAZEPINE AND ANALOGS THEREOF INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT 2017-06-08 US disclosed
US-20170159028-A1 BIOCATALYTIC PROCESS FOR PREPARING ESLICARBAZEPINE AND ANALOGS THEREOF INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT 2017-06-08 US disclosed
US-9605290-B2 Biocatalytic process for preparing eslicarbazepine and analogs thereof CODEXIS, INC. (US) 2017-03-28 US disclosed
US-6384217-B1 INTERMEDIATES FOR PRODUCTION OF CARBAMAZEPINE AND OXCARBAMAZEPINE FARCHEMIA S.R.L. (IT) 2002-05-07 US disclosed
WO-2002006284-A1 INDOLOQUINAZOLINONES NOVARTIS AG (CH) 2002-01-24 WO disclosed
EP-1127877-A2 5-Cyano-10-hydroxy-10,11-dihydro-5H-dibenz[b,f]azepine, processes for its preparation and for its conversion into 5-carbamoyl-10-oxo-10,11-dihydro-5H-dibenz[b,f]azepine or into 5-carbamoyl-5H-dibenz[b,f]azepine FARCHEMIA S.r.l. (IT) 2001-08-29 EP disclosed
US-4579683-A 5-Cyano-10-isonitroso-10,11-dihydro-5H-dibenz[b,f]azepine CIBA-GEIGY CORPORATION (US) 1986-04-01 US disclosed
US-4559174-A NITRATION, REDUCTION AND HYDROLYSIS OF 5-CYANO5H-DIBENZ/B,FLAZEPINE CIBA GEIGY CORPORATION (US) 1985-12-17 US disclosed
US-4540514-A 5-Cyano- and 5-carbamoyl-10-nitro-5H-dibenz[b,f]azepine CIBA-GEIGY CORPORATION (US) 1985-09-10 US disclosed
EP-0028028-B1 PROCESSES FOR THE PREPARATION OF AN OXO COMPOUND, AND INTERMEDIATES REQUIRED THEREFOR CIBA-GEIGY AG (CH) 1985-05-22 EP disclosed
US-4452738-A Process for the manufacture of 5-carbamoyl-10-oxo-10,11-dihydro-5H-dibenz[b,]azepine CIBA-GEIGY CORPORATION (US) 1984-06-05 US disclosed
EP-0028028-A2 Processes for the preparation of an oxo compound, and intermediates required therefor CIBA-GEIGY AG (CH) 1981-05-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170159028-A1 BIOCATALYTIC PROCESS FOR PREPARING ESLICARBAZEPINE AND ANALOGS THEREOF BACE1, BACE2, GSAP KMT2A 306/4885ALDH1A1 281/4885MEN1 3740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.